Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bradley Vilims

Interventional Pain Medicine Lakewood, CO Medical Doctor

NPI 1881664944 CMS profile 702077

325 Teller St, Suite 240, Lakewood, CO 80226

Open in the dashboard

General payments

$978,216

37 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$281,250

7 holdings reported · through program year 2025

Through program year 2025, Bradley Vilims of Lakewood, CO is reported in the CMS Open Payments database as having received $978,216 across 37 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $281,250 across 7 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

14 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $72,355 5
2024 General $90,589 6
2023 General $115,840 9
2022 General $136,805 4
2021 General $185,776 5
2020 General $159,151 4
2019 General $217,701 4
2025 Ownership $43,750 1
2024 Ownership $43,750 1
2023 Ownership $43,750 1
2022 Ownership $43,750 1
2021 Ownership $43,750 1
2020 Ownership $31,250 1
2019 Ownership $31,250 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bradley Vilims
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Bradley Vilims were reported at $72,355. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Bradley Vilims Interventional Pain Medicine median Middle half National median
2019 $217,701 $684 $216–$2,079 $163
2020 $159,151 $382 $122–$1,109 $114
2021 $185,776 $552 $167–$1,554 $132
2022 $136,805 $605 $187–$1,924 $149
2023 $115,840 $671 $195–$1,915 $160
2024 $90,589 $684 $206–$1,837 $164
2025 $72,355 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $977,131 29 payments
  2. Relievant Medsystems, Inc. $837 5 payments
  3. Saluda Medical Americas, Inc. $247 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $951,408 28 payments
  2. Consulting Fee $25,723 1 payment
  3. Travel and Lodging $618 2 payments
  4. Food and Beverage $467 6 payments
Products named General payments · program years 2019–2025
  1. IonicRF Generator $185,776 5 payments
  2. Cardiovascular- Research only $113,161 2 payments
  3. Neuromodulation Dspsbls and Accs $107,777 3 payments
  4. CRM-Research only $104,539 2 payments
  5. IonicRF $68,636 2 payments
  6. Cardiovascular-Research Only $51,374 1 payment
  7. NT2000IX $34,408 1 payment
  8. PENTA $17,497 1 payment
  9. Intracept Pain $837 5 payments
  10. Intracept Pain $837 5 payments
  11. Other $1,922 13 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

398

Median for Interventional Pain Management: 1,220

Drug cost

$14,109

Median for Interventional Pain Management: $39,344

Branded share of claims

15.8%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycontin Oxycodone Hcl Brand 12 $3,774
Oxycodone Hcl Generic 126 $3,286
Morphine Sulfate Er Morphine Sulfate Brand 25 $2,006
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 26 $1,670
Methadone Hcl Generic 57 $1,263
Hydromorphone Hcl Generic 26 $710
Pregabalin Generic 26 $368
Hydroxyzine Pamoate Generic 11 $251
Zaleplon Generic 11 $204
Clonazepam Generic 14 $168

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Records

37 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record